PDE5A and metabolic dysfunction-associated steatohepatitis: Our current study showed for the first time that anti-fibrotic effects induced by the PDE5 inhibitor are reflected by differentially expressed miRNAs in the liver and that some of these changes can be monitored in plasma exosomes, suggesting that miRNA profiling of plasma exosomes might be used as a useful biomarker for addressing effects during NASH progression and treatment with drugs which needs to be assessed in ongoing and future human studies.